Tribune Therapeutics is a pre-clinical stage biopharmaceutical company developing novel biological drugs to treat patients with fibrotic diseases, including diseases affecting the kidney, lung and liver.

Based on research from Håvard Attramadal‘s lab at Oslo University Hospital, Tribune’s medicines target the CCN protein family. The CCN protein family is a group of signalling proteins central to the development of fibrosis; the process of exaggerated scar tissue formation. The most well known protein in the CCN family is CCN2, also known as Connective Tissue Growth Factor (CTGF). However, several of the other CCN family members have also been shown to be important drivers of fibrosis, and thus according to the company broader inhibition has a greater anti-fibrotic potential than solely targeting CCN2.

Founded in 2020, the company officially launched in June 2021 with seed funding from HealthCap and Novo Holdings. Prior to the company being founded the Research Council of Norway provided funding to help with commercialization. During that work potential indications under investigation included Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease.